Pharmacokinetics of meropenem in patients with intra-abdominal infections.
about
Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effectsPharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Pharmacokinetic and pharmacodynamic properties of meropenem.Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.Carbapenem susceptibility breakpoints, clinical implications with the moving target.An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.Peritoneal pharmacokinetics and pharmacodynamic target attainment of meropenem in patients undergoing abdominal surgery.Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.Determination of meropenem in plasma by high-performance liquid chromatography and a microbiological method.Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
P2860
Q28260317-46E2DEA6-EDBB-48FC-8DD1-546EE525318EQ33697176-4C37396A-7006-4D95-B1D2-FF2A7C4060B9Q33770046-0DC184EF-6ED3-411B-B2FC-0576E7CE21A2Q37247125-7A5C639E-471A-49C8-B5C1-19FFBE1658D3Q37308807-5D97109B-0384-4440-8B38-8144A7DF4B4FQ38650049-3D5E3494-7FC8-4CF7-9F85-EDCFEA2BD44DQ38749988-BBBAB017-141E-48DC-BE17-1E0572340A2FQ38751264-CA7D0302-6094-422D-B82F-B3F8A9AF0B7EQ40506427-610146E2-02FB-47FF-99A5-5E6B357B95ABQ43077125-DEF94D0A-DD9F-4767-B107-216C3E5CBEC9Q45954223-6A9FC90A-1B30-4CEA-AE64-E97CEEA5B0ABQ46592051-62A183C3-42DD-4E51-973D-470A25BC981DQ47337023-9CC9E169-9CB8-4E70-9145-3624BC851E00Q53979811-C7AA484B-B181-45A1-9A7F-CF2509829B42Q54766719-7C327D91-7766-4C88-AF63-DDC3F4DDC8EE
P2860
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
@ast
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
@en
type
label
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
@ast
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
@en
prefLabel
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
@ast
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of meropenem in patients with intra-abdominal infections.
@en
P2093
Appleman MD
Bedikian A
Heseltine PN
Nakahiro RK
Okamoto MP
P2860
P304
P356
10.1128/AAC.38.1.151
P407
P577
1994-01-01T00:00:00Z